Stay updated with breaking news from Avenge Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NATICK, Mass. and QUINCY, Mass., Nov. 20, 2023 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of
The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes.
The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,
Investegate announcements from NMD Pharma, Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors